tezepelumab vs WIN378

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

tezepelumab · Tezspire

Marketed by AstraZeneca and partners

Approved in Asthmamonoclonal antibody
Reliable signal

NCT03347279 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.

Next expected readout: November 2026 · NCT06705764 (registry estimate)

Reported efficacy

Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.); Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL (From randomisation to Study Week 52.): Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39) (met)

Result source: NCT03347279

WIN378

Developed by Windward Bio and partners

Phase 2/3 in Asthmamonoclonal antibody
Weak signal

NCT05790694 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events" (with 6 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2028 · NCT07120503 (registry estimate)

Reported efficacy

Adverse events (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-AUC0-last (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Tmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Cmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-CL/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Vd/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-T1/2 (Strat of Treatment to end of study (approsimately 160days)): In 50 healthy adults given single doses of 20, 60, 200, 600 or 900 mg (eight on drug and two on placebo at each level), treatment-emergent adverse events were comparable between dose groups and placebo, with no trend for increasing risk with dose escalation. Anti-drug antibody incidence was 5% (2 of 40), no injection site reactions occurred, mean half-life ranged from 55.0 to 65.8 days, and exposure increased in a near dose-proportional manner from 20 to 900 mg.

Result source: NCT05790694

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtezepelumabWIN378
Severe exacerbations, annualised rate0.9 vs 2.1−1.2 vs placebo210mg Q4W · wk 52 · n 528NCT03347279
6 other results
  • 0.2 vs 0.7 210 mg · wk 52 · n 137 · Phase 2 · primary NCT02054130
  • 0.2 vs 0.7 280 mg · wk 52 · n 137 · Phase 2 · primary NCT02054130
  • 0.3 vs 0.7 70 mg · wk 52 · n 138 · Phase 2 · primary NCT02054130
  • 0.0 vs 0.1 210 mg · wk 52 · n 137 · Phase 2 · secondary NCT02054130
  • 0.0 vs 0.1 280 mg · wk 52 · n 137 · Phase 2 · secondary NCT02054130
  • 0.0 vs 0.1 70 mg · wk 52 · n 138 · Phase 2 · secondary NCT02054130
—Not reported
Trough FEV1, change—Not posted · NCT05280418—Not reported
ACQ-5, change—Not posted · NCT05280418—Not reported
OCS dose reduction—Not posted · NCT05280418—Not reported

Severe exacerbations, annualised rate

tezepelumab
0.9 vs 2.1−1.2 vs placebo210mg Q4W · wk 52 · n 528NCT03347279
6 other results
  • 0.2 vs 0.7 210 mg · wk 52 · n 137 · Phase 2 · primary NCT02054130
  • 0.2 vs 0.7 280 mg · wk 52 · n 137 · Phase 2 · primary NCT02054130
  • 0.3 vs 0.7 70 mg · wk 52 · n 138 · Phase 2 · primary NCT02054130
  • 0.0 vs 0.1 210 mg · wk 52 · n 137 · Phase 2 · secondary NCT02054130
  • 0.0 vs 0.1 280 mg · wk 52 · n 137 · Phase 2 · secondary NCT02054130
  • 0.0 vs 0.1 70 mg · wk 52 · n 138 · Phase 2 · secondary NCT02054130
WIN378
—Not reported

Trough FEV1, change

tezepelumab
—Not posted · NCT05280418
WIN378
—Not reported

ACQ-5, change

tezepelumab
—Not posted · NCT05280418
WIN378
—Not reported

OCS dose reduction

tezepelumab
—Not posted · NCT05280418
WIN378
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

WIN378: no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. tezepelumab: 4 of 4 rows · WIN378: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictezepelumab
Dropout rate
3%210mg Q4Wa
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 19 more results
0.9%210 mg Q4W
NCT03968978 · Phase 3 · Asthma · phase 3
8.1%
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
7.5%210mg Q4W
NCT03927157 · Phase 3
10.9%210 mg
NCT02054130 · Phase 2
16.1%280 mg
NCT02054130 · Phase 2
8%70 mg
NCT02054130 · Phase 2
10.8%
NCT05329194 · Phase 4 · registry result, not featured evidence
8.4%
NCT05274815 · Phase 3 · registry result, not featured evidence
2.9%
NCT05062759 · Phase 3 · registry result, not featured evidence
—NAVIGATOR Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
3%NAVIGATOR Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
—SOURCE Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
8.1%SOURCE Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
0%210 mg Q4W
NCT04048343 · Phase 3 · registry result, not featured evidence
1.7%210 mg Q4W
NCT03688074 · Phase 2 · registry result, not featured evidence
0%
NCT04673630 · Phase 1 · registry result, not featured evidence
0%140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
0%140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
12.5%700 mg
NCT01405963 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—210mg Q4Wa
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 19 more results
0.9%210 mg Q4W
NCT03968978 · Phase 3 · Asthma · phase 3
—
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
0.5%210mg Q4W
NCT03927157 · Phase 3
—210 mg
NCT02054130 · Phase 2
—280 mg
NCT02054130 · Phase 2
—70 mg
NCT02054130 · Phase 2
—
NCT05329194 · Phase 4 · registry result, not featured evidence
0.3%
NCT05274815 · Phase 3 · registry result, not featured evidence
—
NCT05062759 · Phase 3 · registry result, not featured evidence
—NAVIGATOR Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
—NAVIGATOR Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
—SOURCE Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
—SOURCE Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
—210 mg Q4W
NCT04048343 · Phase 3 · registry result, not featured evidence
0%210 mg Q4W
NCT03688074 · Phase 2 · registry result, not featured evidence
—
NCT04673630 · Phase 1 · registry result, not featured evidence
—140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
—140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
6.3%700 mg
NCT01405963 · Phase 1 · registry result, not featured evidence
Serious AEs
9.8%210mg Q4Wa
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 19 more results
4.5%210 mg Q4W
NCT03968978 · Phase 3 · Asthma · phase 3
16.2%
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
8%210mg Q4W
NCT03927157 · Phase 3
9.5%210 mg
NCT02054130 · Phase 2
13.1%280 mg
NCT02054130 · Phase 2
12.3%70 mg
NCT02054130 · Phase 2
10.8%
NCT05329194 · Phase 4 · registry result, not featured evidence
9.4%
NCT05274815 · Phase 3 · registry result, not featured evidence
0%
NCT05062759 · Phase 3 · registry result, not featured evidence
8.3%NAVIGATOR Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
15.5%NAVIGATOR Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
12.5%SOURCE Pbo to Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
24.3%SOURCE Rand Teze
NCT03706079 · Phase 3 · registry result, not featured evidence
6.2%210 mg Q4W
NCT04048343 · Phase 3 · registry result, not featured evidence
5.1%210 mg Q4W
NCT03688074 · Phase 2 · registry result, not featured evidence
0%
NCT04673630 · Phase 1 · registry result, not featured evidence
0%140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
0%140 mg
NCT02512900 · Phase 1 · registry result, not featured evidence
0%700 mg
NCT01405963 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
210mg Q4Wa
nasopharyngitis 21.4% (placebo 21.5%)
upper respiratory tract infection 11% (placebo 16.6%)
headache 8.1% (placebo 8.5%)
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 19 more results
210 mg Q4W
nasopharyngitis 10.8%
upper respiratory tract infection 8.1%
asthma 5.4%
NCT03968978 · Phase 3 · Asthma · phase 3
nasopharyngitis 16.2% (placebo 25%)
upper respiratory tract infection 12.2% (placebo 10.5%)
asthma 8.1% (placebo 10.5%)
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
210mg Q4W
upper respiratory tract infection 35.3% (placebo 34.2%)
covid-19 14.4% (placebo 12.6%)
suspected covid-19 8% (placebo 12.6%)
NCT03927157 · Phase 3
210 mg
asthma 16.8% (placebo 34.1%)
nasopharyngitis 13.9% (placebo 11.6%)
headache 8% (placebo 4.3%)
NCT02054130 · Phase 2
280 mg
asthma 25.5% (placebo 34.1%)
nasopharyngitis 10.9% (placebo 11.6%)
bronchitis 6.6% (placebo 5.1%)
NCT02054130 · Phase 2
70 mg
asthma 22.5% (placebo 34.1%)
nasopharyngitis 13.8% (placebo 11.6%)
bronchitis 5.1% (placebo 5.1%)
NCT02054130 · Phase 2
alopecia 0.3%
intervertebral disc degeneration 0.3%
ligament sprain 0.3%
NCT05329194 · Phase 4 · registry result, not featured evidence
adrenal insufficiency 0.3%
atrial fibrillation 0.3%
insomnia 0.3%
NCT05274815 · Phase 3 · registry result, not featured evidence
covid-19 22.9% (placebo 22.9%)
acute sinusitis 8.6% (placebo 0%)
skin laceration 5.7% (placebo 0%)
NCT05062759 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.2% (placebo 23.4%)
headache 6.3% (placebo 10.2%)
covid-19 4.9% (placebo 1.5%)
NCT03706079 · Phase 3 · registry result, not featured evidence
nasopharyngitis 24.6% (placebo 23.4%)
upper respiratory tract infection 13.6% (placebo 17.1%)
headache 11% (placebo 10.2%)
NCT03706079 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21.9% (placebo 23.4%)
covid-19 12.5% (placebo 1.5%)
hypertension 12.5% (placebo 4.9%)
NCT03706079 · Phase 3 · registry result, not featured evidence
nasopharyngitis 24.3% (placebo 23.4%)
upper respiratory tract infection 16.2% (placebo 17.1%)
bronchitis 12.2% (placebo 7.3%)
NCT03706079 · Phase 3 · registry result, not featured evidence
210 mg Q4W
nasopharyngitis 20%
pharyngitis 9.2%
back pain 4.6%
NCT04048343 · Phase 3 · registry result, not featured evidence
210 mg Q4W
nasopharyngitis 37.3% (placebo 36.8%)
post procedural complication 18.6% (placebo 17.5%)
cough 10.2% (placebo 7%)
NCT03688074 · Phase 2 · registry result, not featured evidence
covid-19 11.1%
headache 11.1%
nasopharyngitis 11.1%
NCT04673630 · Phase 1 · registry result, not featured evidence
140 mg
bronchitis 18.2%
nasopharyngitis 18.2%
pyrexia 9.1%
NCT02512900 · Phase 1 · registry result, not featured evidence
140 mg
acute sinusitis 10%
contusion 10%
gastritis 10%
NCT02512900 · Phase 1 · registry result, not featured evidence
700 mg
nasopharyngitis 25% (placebo 26.7%)
oropharyngeal pain 18.8% (placebo 6.7%)
asthma 12.5% (placebo 6.7%)
NCT01405963 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tezepelumab

FEV1 0.23 vs 0.1 placebo L @ 52wk210mg Q4W
absolute change · L
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 2 more results
0.35 vs 0.11 placebo L @ 52wk210mg Q4W
NCT03927157 · Phase 3
0.21 vs -0.04 placebo L @ 48wk
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
AQLQ(S)+12 1.48 vs 1.14 placebo score @ 52wk210mg Q4W
absolute change · score
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
ACQ-6 -1.53 vs -1.2 placebo score @ 52wk210mg Q4W
absolute change · score
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 5 more results
-1.34 vs -1.03 placebo score @ 52wk210mg Q4W
NCT03927157 · Phase 3
-1.17 vs -0.89 placebo score @ 52wk210 mg
NCT02054130 · Phase 2
-1.19 vs -0.89 placebo score @ 52wk280 mg
NCT02054130 · Phase 2
-1.24 vs -0.89 placebo score @ 52wk70 mg
NCT02054130 · Phase 2
-0.87 vs -0.51 placebo score @ 48wk
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
Asthma Symptom Diary -0.7 vs -0.59 placebo score @ 52wk210mg Q4W
absolute change · score
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-0.61 vs -0.44 placebo score @ 52wk210mg Q4W
NCT03927157 · Phase 3
Time to First Exacerbation 43.8% (n=528) vs 60.1% (n=531) placebo210mg Q4W
event count · % of participants
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3 · converted to % from 231 Participants as posted
show 1 more result
22.4% (n=201) vs 44.7% (n=199) placebo @ 52wk*210mg Q4W
NCT03927157 · Phase 3 · converted to % from 45 Participants as posted
Rescue Puffs -2.53 vs -2.36 placebo weekly mean rescue medication use @ 52wk210mg Q4W
absolute change · weekly mean rescue medication use
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
WPAI Overall Work Impairment -20.16% (n=185) vs -16.58% (n=177) placebo @ 52wk210mg Q4W
absolute change · percentage points
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
EQ-5D-5L VAS 14.64 vs 11.86 placebo score @ 52wk210mg Q4W
absolute change · score
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
12.8 vs 9.67 placebo score @ 52wk210mg Q4W
NCT03927157 · Phase 3
Morning PEF Change L/Min 34.57 vs 18.01 placebo L/min @ 52wk210mg Q4W
absolute change · L/min
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
46.7 vs 18.96 placebo L/min @ 52wk210mg Q4W
NCT03927157 · Phase 3
Evening PEF Change L/Min 23.87 vs 9.01 placebo L/min @ 52wk210mg Q4W
absolute change · L/min
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
42.14 vs 16.81 placebo L/min @ 52wk210mg Q4W
NCT03927157 · Phase 3
Night-time Awakening -33.51% (n=418) vs -30.22% (n=395) placebo @ 52wk210mg Q4W
absolute change · percentage points
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 2 more results
-18.74% (n=201) vs -15.99% (n=199) placebo @ 52wk210mg Q4W
NCT03927157 · Phase 3
-15.71% (n=59) vs -12.79% (n=70) placebo @ 48wk
NCT03406078 · Phase 3 · monotherapy · Asthma · phase 3
Asthma Exacerbation Free 54.2% (n=528) vs 38.6% (n=531) placebo @ 52wk210mg Q4W
responder rate · % of participants
NCT03347279 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
74.6% (n=201) vs 50.3% (n=199) placebo @ 52wk210mg Q4W
NCT03927157 · Phase 3

+ 70 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tezepelumab's landscape · WIN378's landscape